

Gli studi interventistici in Italia per l'emergenza Covid-19

Data ultimo aggiornamento: 6 luglio 2020

Intervention	Database	ID	Title	Acronym
Acalabrutinib	ClinTrigov	NCT04346199	Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.	CALAVI
Anakinra	AIFA	2020-001167-93	Sobi.IMMUNO-101 emapalumab and anakinra versus standard of care	Sobi.IMMUNO-101
	AIFA	2020-001955-42	BARCIVID Studio sull'utilizzo di baricitinib	BARCIVID
Baricitinib	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
	ClinTrigov	NCT04358614	Baricitinib Therapy in COVID-19	
Bevacizumab	ClinTrigov	NCT04275414	Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia	BEST-CP
	AIFA	2020-001370-30	CAN-COVID - Studio sull'utilizzo di Canakinumab	CAN-COVID
Canakinumab	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Chloroquine	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
	AIFA	2020-001475-33	COLVID-19 Studio randomizzato sull'utilizzo di colchicina	COLVID-19
Colchicine	AIFA	2020-001258-23	CoCOVID Studio sull'utilizzo di colchicina	CoCOVID
	AIFA	2020-001806-42	Home CarE study Colchicina	CHOICE-19
Convalescent plasma	ClinTrigov	NCT04385043	Hyperimmune Plasma in Patients With COVID-19 Severe Infection	COV2-CP
	ClinTrigov	NCT04428021	Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure	PLACO-COVID
	ClinTrigov	NCT04321421	Hyperimmune Plasma for Critical Patients With COVID-19	COV19-PLASMA
	ClinTrigov	NCT04346589	Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients	
	ClinTrigov	NCT04393727	Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19	TSUNAMI
	ClinTrigov	NCT04418531	Convalescent Antibodies Infusion in COVID 19 Patients	
Darunavir/Cobicistat DAS181	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
	ClinTrigov	NCT04354389	DAS181 for STOP COVID-19	
Defibrotide	AIFA	2020-001513-20	DEF-IVID19 - Studio sull'utilizzo di defibrotide	DEF-IVID19
Emapalumab	AIFA	2020-001167-93	Sobi.IMMUNO-101 emapalumab and anakinra versus standard of care	Sobi.IMMUNO-101
	AIFA	2020-001708-41	X-COVID Studio sull'utilizzo di Enoxaparina per la tromboprofilassi di pazienti ospedalizzati COVID-19	X-COVID
Enoxaparin	AIFA	2020-001972-13	Studio sull'utilizzo di eparina a basso peso	COVID-19 HD
	AIFA	2020-001308-40	INHIXACOVID Studio sull'utilizzo di enoxaparina	INHIXACOVID
	AIFA	2020-002214-40	EMOS-COVID - Enoxaparina	EMOS-COVID
Enoxaparin+Methylprednisolone	AIFA	2020-001921-30	STAUNCH - Studio sull'utilizzo di steroidi e eparina	STAUNCH
Eparin+Methylprednisolone	AIFA	2020-001921-30	STAUNCH - Studio sull'utilizzo di steroidi e eparina	STAUNCH
Favipiravir	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
	AIFA	2020-001115-25	HS216C17 Studio di fase 3 sull'utilizzo di favipiravir	HS216C17
	AIFA	2020-001441-39	COP-COV Studio sull'utilizzo di idrossiclorochina in profilassi	COP-COV
	AIFA	2020-001987-28	PRECOV Idrossiclorochina negli operatori sanitari	PRECOV
Hydroxychloroquine	AIFA	2020-001501-24	PROTECT Studio sull'utilizzo di idrossiclorochina	PROTECT
	AIFA	2020-001558-23	Hydro-Stop - somministrazione precoce di idrossiclorochina	Hydro-Stop
	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Hydroxychloroquine+Azitromycin	AIFA	2020-001802-50	AZI-RCT-COVID-19 - Studio sull'utilizzo di idrossiclorochina+azitromicina	AZI-RCT-COVID-19
	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Interferon beta-1a	ClinTrigov	NCT04449380	Clinical Study for the Treatment With Interferon-beta-1a (IFNβ-1a) of COVID-19 Patients	INTERCOP
	ClinTrigov	NCT04438850	COVidIVERmectin: Ivermectin for Treatment of Covid-19	COVER
Ivermectin	AIFA	2020-001528-32	ARCO Studio multi-arm di gestione domiciliare	ARCO
Lopinavir/Ritonavir	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Mavrilimumab	AIFA	2020-001795-15	COMBAT-19 Studio sull'utilizzo di mavrilimumab	COMBAT-19
	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Methylprednisolone	ClinTrigov	NCT04323592	Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome	MP-C19
Nafamostat Mesilate	ClinTrigov	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)	RACONA
Oxytocin	ClinTrigov	NCT04386447	Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19	OsCOVID19
Pamrevlumab	AIFA	2020-001472-14	FibroCov - Studio di fase 2/3 sull'utilizzo di Pamrevlumab	FibroCov
Polyvalent Immunoglobulin	AIFA	2020-002058-26	High dose intravenous polyvalent immunoglobulin in patients with early inflammatory COVID-19	IVIG/H/Covid-19
Prasugrel Hydrochloride	ClinTrigov	NCT04445623	Prasugrel in Severe COVID-19 Pneumonia	PARTISAN
Remdesivir	AIFA	2020-000842-32	GS-US-540-5774 Study: Remdesivir in Participants with Moderate COVID-19	GS-US-540-5774
	AIFA	2020-000841-15	GS-US-540-5773 Study: Remdesivir in Participants with Severe COVID-19	GS-US-540-5773
	AIFA	2020-001366-11	SOLIDARITY - Studio randomizzato OMS	SOLIDARITY
Reparixin	AIFA	2020-001645-40	REPAVID-19 - Studio di fase 2/3 su reparixin	REPAVID-19
	AIFA	2020-001390-76	ESCAPE Studio di fase 2 sull'utilizzo di sarilumab	ESCAPE
Sarilumab	AIFA	2020-001162-12	Sarilumab COVID-19 Sarilumab for hospitalized patients with COVID-19	Sarilumab COVID-19
	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
	AIFA	2020-001745-40	COVID-SARI Studio sull'utilizzo di sarilumab	COVID-SARI
Selinexor	AIFA	2020-001411-25	XPORT-CoV-1001 Studio di fase 2 sull'utilizzo di Selinexor	XPORT-CoV-1001
Siltuximab	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Sitagliptin	ClinTrigov	NCT04365517	The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients	SIDIACO
Tirofiban	ClinTrigov	NCT04368377	Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19	PIC-19
	AIFA	2020-001110-38	Studio TOCIVID-19	TOCIVID-19
	AIFA	2020-001386-37	RCT-TCZ-COVID-19 somministrazione precoce del Tocilizumab	RCT-TCZ-COVID-19
Tocilizumab	AIFA	2020-001154-22	Tocilizumab 2020-001154-22 Tocilizumab in patients with severe COVID-19 pneumonia	Tocilizumab 2020-001154-22
	AIFA	2020-001854-23	AMMURAVID Studio di fase 3 multiarm della SIMIT	AMMURAVID
Tofacitinib	ClinTrigov	NCT04315480	Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis	
	AIFA	2020-002035-30	TOFACOV-2 - Studio sull'utilizzo di Tofacitinib	TOFACOV-2
	ClinTrigov	NCT04332042	TOFACitinib in SARS-CoV2 Pneumonia	
Vitamin C (intravenously)	ClinTrigov	NCT04323514	Use of Ascorbic Acid in Patients With COVID 19	